LBX Pharmacy

LBX Pharmacy (老百姓大药房) is a major Chinese pharmacy retail chain operated by LBX Pharmacy Chain Joint Stock Company (老百姓大药房连锁股份有限公司). Founded in 2001 and headquartered in Changsha, Hunan Province, the company has grown into one of the largest drugstore networks in China, with a presence spanning most provinces and a mix of self-operated and franchised stores. Its core business is the retail sale of prescription and over-the-counter medicines, traditional Chinese medicine, health supplements, personal care products, and medical devices. The chain is known for its large-format, discount-oriented drugstores that emphasize low prices and broad product selection, a model that helped it expand rapidly in the 2000s and 2010s. LBX Pharmacy is listed on the Shanghai Stock Exchange under the ticker 603883, giving it access to public capital for continued expansion. In addition to physical stores, the company has invested in online-to-offline (O2O) and e-commerce channels to serve customers through delivery and digital platforms. It competes with other large Chinese pharmacy chains such as Dashenlin, Yifeng Pharmacy, and Jianzhijia. The brand's Chinese name, 老百姓, literally means 'ordinary people' or 'the common folk,' reflecting a positioning around affordability and accessibility for mass-market consumers. Over the years, LBX Pharmacy has pursued mergers and acquisitions to consolidate regional pharmacy markets and increase its national footprint. It also operates membership programs and health services in stores. The company is a constituent of various consumer and healthcare indices in China. Its growth reflects broader trends in China's pharmaceutical retail sector, including aging demographics, rising chronic disease prevalence, and the separation of hospital drug sales from outpatient pharmacy channels. LBX Pharmacy continues to expand its store count and digital capabilities while navigating regulatory changes in China's healthcare and drug retailing landscape.

LBX Pharmacy emerged in the period when China's pharmacy market was moving from a highly fragmented collection of independently operated drugstores toward larger, more standardized chains. Its operating base in Changsha placed it within Hunan's developing commercial and healthcare-services economy, while the chain format enabled centralized purchasing, distribution, store training, and compliance management. The company's growth model has combined the opening of new pharmacies with the development of a broader retail-health platform. Rather than limiting stores to prescription dispensing, LBX has carried over-the-counter medicines, traditional Chinese medicines, medical supplies, nutritional products, personal care, and other health-related categories. This broader assortment supports recurring community demand and helps stores serve both acute needs and long-term conditions such as chronic disease. As the Chinese pharmacy sector matured, branded chains increasingly competed on location density, product availability, price, pharmacist services, supply-chain efficiency, and consumer trust. Public-market access further distinguished LBX from small independent operators, providing a framework for capital raising and corporate governance but also imposing continuing disclosure and regulatory responsibilities. The company subsequently participated in the sector's wider consolidation trend, in which larger chains expanded their geographic reach and operating scale through a mixture of organic development and regional integration. The modern LBX model also reflects the convergence of physical pharmacy retail and digital healthcare commerce. Consumers may use online channels for product discovery, ordering, delivery, and repeat purchases, while regulated prescription dispensing and other professional services remain subject to applicable Chinese rules. The brand's continuing identity is therefore that of an integrated pharmacy retailer rather than a single-product pharmaceutical label. Current details concerning store numbers, regional subsidiaries, digital platforms, and management should be confirmed through the company's latest annual report and investor disclosures.

• 2015

  Public listing

  [2]Shanghai Stock Exchangesse.com.cn

  The operating company became listed on the Shanghai Stock Exchange, marking a transition to a publicly traded pharmacy-retail enterprise.

• 2001

  Business established

  [1]LBX Pharmacy official websitelbxpharmacy.com

  LBX Pharmacy was established in China and began developing a branded chain-pharmacy business.

A nationwide Chinese community-pharmacy and health-retail chain focused on accessible medicines, professional dispensing, consumer health products, and standardized pharmacy services.

• Pharmacy retail

  Prescription medicines

  Prescription medicines are a core part of the chain's pharmacy proposition. Dispensing, availability, and online fulfillment are governed by Chinese pharmaceutical, licensing, and prescription-management requirements, so the precise assortment and service model can differ by location.

• Pharmacy retail

  Over-the-counter medicines

  The chain sells non-prescription medicines for common conditions and everyday healthcare needs. OTC products extend the store's role beyond prescription fulfillment and are typically supported by pharmacist or staff guidance and consumer-facing product information.

• Pharmacy retail

  Traditional Chinese medicines

  Traditional Chinese medicine products form part of the broader assortment offered by Chinese pharmacy chains. Depending on the store and applicable rules, this category may include prepared medicines, proprietary products, and related health goods.

• Consumer health

  Health and medical products

  LBX stores also address adjacent consumer-health needs through medical devices and supplies, vitamins, nutritional products, health foods, personal-care items, and other wellness merchandise. These categories diversify revenue and encourage regular community-pharmacy visits.

• 2024

  Controller Xie Zilong placed under detention, later lifted in September

  In 2024, Xie Zilong, the actual controller and chairman of LBX Pharmacy, was placed under detention, drawing attention to the company's corporate governance; the detention was lifted in September of the same year. The cited information does not provide a final criminal conviction, and the detention is not automatically written as a finding of bribery.

  Source 1Source 2

Read more

1. 1LBX Pharmacy official websitelbxpharmacy.com
2. 2Shanghai Stock Exchangesse.com.cn
3. 3LBX Pharmacy - Wikidatawikidata.org
4. 4老百姓大藥房 - 维基百科zh.wikipedia.org
5. 5Controller Xie Zilong placed under detention, later lifted in Septemberm.eeo.com.cn
6. 6Controller Xie Zilong placed under detention, later lifted in Septemberm.jiemian.com
7. 7方源资本完成对老百姓大药房的战略入股，助推医药零售行业整合再升级news.pedaily.cn
8. 8健易保推出“行程无忧”公益计划，助力医药和保险公司共抗疫情tech.sina.com.cn
9. 9老百姓关于公司董事辞职的公告finance.sina.com.cn